1
Duane A Burnett, Wen Lian Wu: Piperidine based MCH antagonists for treatment of obesity and CNS disorders. Schering Corporation, William Y Lee, December 16, 2003: US06664273 (26 worldwide citation)

The present invention discloses compounds, which are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them ...


2

3
Bandarpalle B Shankar, Razia K Rizvi, Joseph A Kozlowski, Neng Yang Shih: Cannabinoid receptor ligands. Schering Corporation, Keith D MacMillan, Thomas A Blinka, William Y Lee, January 5, 2010: US07642272 (22 worldwide citation)

There are disclosed compounds of the formula I a pharmaceutically acceptable salt or solvate of the compound, which exhibit anti-inflammatory and immunomodulatory activity. Also disclosed are pharmaceutical compositions containing said compounds.


4
Zhaoning Zhu, Brian McKittrick, Zhong Yue Sun, Yuanzan C Ye, Johannes H Voigt, Corey O Strickland, Elizabeth M Smith, Andrew Stamford, William J Greenlee, Robert D Mazzola, John P Caldwell, Jared N Cumming, Lingyan Wang, Yusheng Wu, Ulrich Iserloh, Xiaoxiang Liu, Tao Guo, Thuy X E Le, Kurt W Saionz, Suresh D Babu, Rachael C Hunter, Michelle L Morris, Huizhong Gu, Gang Qian, Dawit Tadesse, Ying Huang, Guoqing Li, Jianping Pan, Jeffrey A Misiaszek, Gaifa Lai, Jingqi Duo, Chuanxing Qu, Yuefei Shao: Heterocyclic aspartyl protease inhibitors. Schering Corporation, Pharmacopeia, Keith D MacMillan, William Y Lee, July 27, 2010: US07763609 (20 worldwide citation)

Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O)2—, —C(═O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(═N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, ...


5
Samuel Chackalamannil, Mariappan V Chelliah, Martin C Clasby, Yan Xia: Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists. Schering Corporation, Gerard E Reinhardt, William Y Lee, May 2, 2006: US07037920 (16 worldwide citation)

Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salts thereof, wherein: n1 and n2 are independently 0-2; Het is an optionally substituted mono-, bi- or tricyclic heteroaromatic group; B is alkyl or optionally substituted alkenyl; R22 is —COR23 or a carboxy, sulfin ...


6
Zhaoning Zhu, Brian McKittrick, Andrew Stamford, William J Greenlee, Xiaoxiang Liu, Mihirbaran Mandal, Johannes H Voigt, Corey O Strickland: Aspartyl protease inhibitors. Schering Corporation, Keith D MacMillan, William Y Lee, Gerard M Devlin, January 11, 2011: US07868000 (11 worldwide citation)

Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein j, k, U, W, R, R1, R2, R3, R4, R6, R7 and R7a are as described above in the specification. Also disclosed is the method of inhibiting aspartyl protease, and in partic ...


7
Zhaoning Zhu, Brian McKittrick, Zhong Yue Sun, Yuanzan C Ye, Johannes H Voigt, Corey Strickland, Elizabeth M Smith, Andrew Stamford, William J Greenlee, Robert Mazzola, John Caldwell, Jared N Cumming, Lingyan Wang, Yusheng Wu, Ulrich Iserloh, Tao Guo, Thuy X H Le, Kurt W Saionz, Suresh D Babu, Rachael C Hunter: Heterocyclic aspartyl protease inhibitors. Schering Corporation, Keith D MacMillan, William Y Lee, September 22, 2009: US07592348 (10 worldwide citation)

Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O)2—, —C(═O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(═N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, ...


8
William J Greenlee, Ying Huang, Joseph M Kelly, Stuart W McCombie, Andrew W Stamford, Yusheng Wu: Substituted urea neuropeptide Y Y5 Receptor antagonists. Schering Corporation, William Y Lee, May 17, 2005: US06894063 (10 worldwide citation)

A novel class of compounds such as antagonists of the neuropeptide Y Y5 receptor, methods of making such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, pre ...


9
Andrew W Stamford, Ying Huang, Guoqing Li: Neuropeptide Y Y5 receptor antagonists. Schering Plough Corporation, William Y Lee, December 23, 2003: US06667319 (10 worldwide citation)

The present invention discloses compounds which, are novel receptor antagonists for NPY Y5 as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such NPY Y5 receptor antagonists as well as methods of using them to treat ...


10
Joseph A Kozlowski, Bandarpalle B Shankar, Neng Yang Shih, Ling Tong: Cannabinoid receptor agonists. Schering Corporation, William Y Lee, May 15, 2007: US07217732 (9 worldwide citation)

A compound of the formula or a pharmaceutically acceptable salt thereof, wherein: R1, R2, R3, R4, R5, R6, L1, L2, M, n, p, X, Y and Z are as described in the specification; pharmaceutical compositions thereof, methods of making said pharmaceutical compositions; and methods of use thereof.